In previous clinical studies1–6, SGLT2 inhibitors showed consistent positive effects on renal outcomes and reducing heart failure hospitalisation, regardless of the clinical background of the patients (i.e., with or without diabetes or high ASCVD risk). The gene discussed is SLC5A2; the disease is diabetes mellitus.